Correlation Between Eliem Therapeutics and AC Immune

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Eliem Therapeutics and AC Immune at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eliem Therapeutics and AC Immune into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eliem Therapeutics and AC Immune, you can compare the effects of market volatilities on Eliem Therapeutics and AC Immune and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eliem Therapeutics with a short position of AC Immune. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eliem Therapeutics and AC Immune.

Diversification Opportunities for Eliem Therapeutics and AC Immune

-0.53
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Eliem and ACIU is -0.53. Overlapping area represents the amount of risk that can be diversified away by holding Eliem Therapeutics and AC Immune in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AC Immune and Eliem Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eliem Therapeutics are associated (or correlated) with AC Immune. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AC Immune has no effect on the direction of Eliem Therapeutics i.e., Eliem Therapeutics and AC Immune go up and down completely randomly.

Pair Corralation between Eliem Therapeutics and AC Immune

Given the investment horizon of 90 days Eliem Therapeutics is expected to generate 6.59 times more return on investment than AC Immune. However, Eliem Therapeutics is 6.59 times more volatile than AC Immune. It trades about 0.16 of its potential returns per unit of risk. AC Immune is currently generating about -0.22 per unit of risk. If you would invest  280.00  in Eliem Therapeutics on January 30, 2024 and sell it today you would earn a total of  118.00  from holding Eliem Therapeutics or generate 42.14% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Eliem Therapeutics  vs.  AC Immune

 Performance 
       Timeline  
Eliem Therapeutics 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Eliem Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Eliem Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.
AC Immune 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days AC Immune has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain comparatively stable which may send shares a bit higher in May 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Eliem Therapeutics and AC Immune Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Eliem Therapeutics and AC Immune

The main advantage of trading using opposite Eliem Therapeutics and AC Immune positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eliem Therapeutics position performs unexpectedly, AC Immune can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AC Immune will offset losses from the drop in AC Immune's long position.
The idea behind Eliem Therapeutics and AC Immune pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Other Complementary Tools

Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Money Managers
Screen money managers from public funds and ETFs managed around the world
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities